Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
As of close of business last night, Strata Critical Medical Inc’s stock clocked out at $4.85, up 0.21% from its previous closing price of $4.84. In other words, the price has increased by $0.21 from its previous closing price. On the day, 0.65 million shares were traded. SRTA stock price reached its highest trading level at $4.945 during the session, while it also had its lowest trading level at $4.81.
Ratios:
To gain a deeper understanding of SRTA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.39 and its Current Ratio is at 4.39. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On February 26, 2025, Lake Street started tracking the stock assigning a Buy rating and target price of $6.50.
On July 18, 2023, Ladenburg Thalmann started tracking the stock assigning a Buy rating and target price of $13.Ladenburg Thalmann initiated its Buy rating on July 18, 2023, with a $13 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 09 ’25 when Heyburn William A. bought 17,000 shares for $4.47 per share. The transaction valued at 76,044 led to the insider holds 1,403,436 shares of the business.
LAUCK ANDREW bought 5,000 shares of SRTA for $21,825 on Dec 05 ’25. The Director now owns 135,642 shares after completing the transaction at $4.37 per share. On Nov 20 ’25, another insider, Love Reginald, who serves as the Director of the company, sold 11,000 shares for $4.37 each. As a result, the insider received 48,070 and left with 113,897 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SRTA now has a Market Capitalization of 418877664 and an Enterprise Value of 61245240. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.83 while its Price-to-Book (P/B) ratio in mrq is 1.47. Its current Enterprise Value per Revenue stands at 0.912 whereas that against EBITDA is -1.988.
Stock Price History:
The Beta on a monthly basis for SRTA is 1.97, which has changed by 0.13882351 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, SRTA has reached a high of $6.02, while it has fallen to a 52-week low of $2.35. The 50-Day Moving Average of the stock is 1.84%, while the 200-Day Moving Average is calculated to be 17.97%.
Shares Statistics:
It appears that SRTA traded 829.81K shares on average per day over the past three months and 795130 shares per day over the past ten days. A total of 86.05M shares are outstanding, with a floating share count of 60.99M. Insiders hold about 29.38% of the company’s shares, while institutions hold 52.77% stake in the company. Shares short for SRTA as of 1765756800 were 5998697 with a Short Ratio of 7.23, compared to 1763078400 on 3999733. Therefore, it implies a Short% of Shares Outstanding of 5998697 and a Short% of Float of 10.290000000000001.
Earnings Estimates
. The current market rating for Strata Critical Medical Inc (SRTA) reflects the collective analysis of 1.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.05, with high estimates of -$0.05 and low estimates of -$0.05.
Analysts are recommending an EPS of between -$0.15 and -$0.15 for the fiscal current year, implying an average EPS of -$0.15. EPS for the following year is $0.08, with 1.0 analysts recommending between $0.08 and $0.08.
Revenue Estimates
In. The current quarter, 2 analysts expect revenue to total $60.35M. It ranges from a high estimate of $60.7M to a low estimate of $60M. As of. The current estimate, Strata Critical Medical Inc’s year-ago sales were $54.36MFor the next quarter, 2 analysts are estimating revenue of $62.7M. There is a high estimate of $62.7M for the next quarter, whereas the lowest estimate is $62.7M.
A total of 2 analysts have provided revenue estimates for SRTA’s current fiscal year. The highest revenue estimate was $237.3M, while the lowest revenue estimate was $190.4M, resulting in an average revenue estimate of $213.85M. In the same quarter a year ago, actual revenue was $248.69MBased on 2 analysts’ estimates, the company’s revenue will be $266.5M in the next fiscal year. The high estimate is $270M and the low estimate is $263M.
